Evidence map›Paper›PMID 38549859›Full record

ReviewFrontiers in genetics2024

Intelligent computation in cancer gene therapy.

Roee Samuel, Ramez Daniel

Abstract readReview
In one paragraph

Review in Frontiers in genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Roee SamuelDepartment of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Ramez DanielDepartment of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the use of gene therapy for the treatment of disease has gained substantial interest, both in academic research and in the biomedical industry. Initial experimentation in gene therapy has generated positive results, as well as questions regarding safety. However, lessons have been learned from these first investigations, among them a realization that such treatments require a method to fine-tune the expression of therapeutic genes in real-time. A logical solution to this problem arose through the field of synthetic biology in the form of synthetic gene circuits. Thus, the synthetic biology community today aims to create "smart cells" for a variety of gene therapy applications, in an attempt to precisely target malignant cells while avoiding harming healthy ones. To generate safer and more effective gene therapies, new approaches with emerging computational abilities are necessary. In this review, we present several computational approaches which allow demonstrating artificial intelligence in living cells. Specifically, we will focus on implementing artificial neural networks using synthetic gene regulatory networks for cancer therapy and discuss the state-of-the-art computational developments.

Indexed as

analog computationartificial neural networksdigital computationgene circuitsgene therapy

Identifiers

PMID38549859
PMCPMC10973118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.